Bristol Myers: Opdivo Failed to Meet Endpoint in Key Lung-Cancer Study – Wall Street Journal

Bristol Myers: Opdivo Failed to Meet Endpoint in Key Lung-Cancer Study
Wall Street Journal
A cancer drug's surprise failure in a clinical trial wiped $20 billion off Bristol-Myers Squibb Co. BMY -15.99 % 's market value Friday, and raised questions about one of the industry's hottest research areas: drugs that harness the body's immune …
Bristol-Myers Squibb's Bad News Buoys MerckBarron’s
Bristol-Myers Squibb's lucrative Opdivo fails lung cancer trailNew York Post
Cancer bet bites Bristol-Myers investorsThe Mercury News
Reuters –CNBC –The Boston Globe –Bloomberg
all 165 news articles »